BionimeTPE:4737 -0.18%65 Median PS Value is NT$58.17 as of Jun. 28, 2026, which is 100% below its 10-year median of 1.22. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.96 (Fairly Valued). The stock has 7 warning signs investors should review. Among 337 Medical Devices & Instruments companies, Bionime ranks worse than 73.59% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Bionime's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$27.052. Bionime's 10-Year median PS Ratio is 2.1503. Therefore, the Median PS Value for today is NT$58.17.
As of today (2026-06-28), Bionime's share price is NT$57.00. Bionime's Median PS Value is NT$58.17. Therefore, Bionime's Price to Median PS Value for today is 0.98.
The historical rank and industry rank for Bionime's Median PS Value or its related term are showing as below:
TPE:4737'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.97 Med: 1.22 Max: 1.34
Current: 0.98
During the past 13 years, the highest Price to Median PS Value of Bionime was 1.34. The lowest was 0.97. And the median was 1.22.
TPE:4737's Price-to-Median-PS-Value is ranked worse than 73.59% of 337
companies
in the Medical Devices & Instruments industry
Industry Median: 0.71
vs TPE:4737: 0.98
Bionime (TPE:4737) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Bionime's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
57.00
/
58.17
=
0.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime Median PS Value Related Terms
Bionime Median PS Value Historical Data
* Premium members only.
The historical data trend for Bionime's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4737 vs ISRG, BDX, MDLN: Median PS Value Comparison
For the Medical Instruments & Supplies subindustry, Bionime's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Bionime's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.1503.
Bionime's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$27.052.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a Median PS Value of NT$58.17 as of Jun. 28, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Bionime and its competitors. This is 4668% above median its historical median of 1.22. Over the past decade, Bionime's Median PS Value has ranged from 0.97 to 1.34. According to the industry distribution chart, Bionime ranks #248 out of 337 companies in the Medical Devices & Instruments industry, placing it in the top 73.6%.
Is Bionime's Median PS Value too high?
Bionime's current Median PS Value of NT$58.17 is 4668% above median its 10-year median of 1.22. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 1.34. Based on the distribution chart, Bionime ranks #248 out of 337 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Median PS Value compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #248 out of 337 companies for Median PS Value. This places Bionime in the lower half of its industry. The industry median Median PS Value is 0.71. Historically, Bionime's own Median PS Value has ranged from 0.97 to 1.34 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Bionime and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionime's current Median PS Value is NT$58.17, which is 4668% above median its own 10-year median of 1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.96, compared to a current price of NT$57.00 — trading 3.3% below its estimated fair value. The current Median PS Value is NT$58.17, which is 4668% above median its 10-year median of 1.22. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Bionime (TPE:4737), the current Median PS Value is NT$58.17 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be undervalued.
The current stock price of NT$57.00 is trading 3.3% below its estimated GF Value™ of NT$58.96.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
Median PS Value: NT$58.17 (4668% above median its 10-year median of 1.22)
GF Value™: NT$58.96 vs. price of NT$57.00 (3.3% below fair value)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score
Get the complete analysis for TPE:4737
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
